Clinical trial
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for…
NCT00006269 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00006269 |
|---|---|
| Title | Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer |
| Official title | A Prospective, Randomized Trial of Sandostatin LAR Depot for the Prevention of Irinotecan-Induced Diarrhea in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Diarrhea |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, octreotide acetate |
| Enrollment | 89 |
| Start date | Dec 1, 1999 |
| Primary completion | Dec 1, 1999 |
| First posted | May 24, 2004 |
| Last update posted | May 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: